Adlai Nortye Ltd. American Depositary Shares (ANL) Financial Analysis & Valuation | Quarter Chart

Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squam... more
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development o... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$782.93MExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryKYCEOYang Lu
IPO Date2023-09-29CAGR
Employees109Websitewww.adlainortye.com
Div. YieldPayout Ratio
Buy Back YieldTotal Yield
ANL chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$99.51MP/E-10.61Forward P/E-53.44PEG
P/S31.83P/B0.87P/CF-3.23P/FCF-10.76
Sales$19.68MSales 1Y203.24%Sales 3YSales 5Y
EPS$-1.39EPS 1Y-72.32%EPS 3YEPS 5Y
Sales QoQEPS QoQSales QoQ Avg107.29%EPS QoQ Avg-32.02%
Gross Margin100%Operating Margin-113.28%Profit Margin-114.48%ROCE-9.99%
ROA-9%ROE-22%Altman Z Score12.02Piotroski Score2
Current Ratio9.55Quick Ratio9.55Cash Ratio5.26Op. CF Ratio-0.3
Debt/Equity0.12Debt/Assets0.11Lt Debt/Equity0.04Lt Debt/Cap.0.03
Intrst Cov.Inventory TurnoverAsset Turnover0.08Receivables Turnover74.55
Enterprise Value$99.51MP/E Ratio-10.61
Forward P/E-53.44PEG Ratio
P/S Ratio31.83P/B Ratio0.87
P/CF Ratio-3.23P/FCF Ratio-10.76
EPS$-1.39EPS Growth 1Y-72.32%
EPS Growth 3YEPS Growth 5Y
Revenue Growth 1Y203.24%Gross Margin1%
Operating Margin-1.13%Profit Margin-1.14%
ROE-0.22%ROA-0.09%
ROCE-0.1%Current Ratio9.55
Quick Ratio9.55Cash Ratio5.26
Debt/Equity0.12Interest Coverage
Altman Z Score12.02Piotroski Score2

Adlai Nortye Ltd. American Depositary Shares (ANL) valuation & financials

Adlai Nortye Ltd. American Depositary Shares (ANL) has a market capitalization of $782.93M and trades at a price-to-earnings ratio of -10.6. It operates in the Healthcare sector (Biotechnology).

Adlai Nortye Ltd. American Depositary Shares's revenue grew +203.2% over the last year.

Adlai Nortye Ltd. American Depositary Shares's next earnings report is scheduled for March 3, 2027; analysts estimate EPS of $-0.13. Check the earnings calendar to see all companies reporting this week.

📈 Analysts estimate ANL EPS of $-0.13 for the upcoming quarter. See Adlai Nortye Ltd. American Depositary Shares revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Adlai Nortye Ltd. American Depositary Shares (ANL) — frequently asked questions

When does Adlai Nortye Ltd. American Depositary Shares (ANL) report earnings next?

Adlai Nortye Ltd. American Depositary Shares is expected to report earnings on March 3, 2027. Analysts estimate EPS of $-0.13.

What is Adlai Nortye Ltd. American Depositary Shares's market cap?

Adlai Nortye Ltd. American Depositary Shares (ANL) has a market capitalization of $782.93M.

What is ANL's P/E ratio?

Adlai Nortye Ltd. American Depositary Shares trades at a price-to-earnings ratio of -10.6, with trailing twelve-month EPS of $-1.39.

How fast is Adlai Nortye Ltd. American Depositary Shares growing?

Adlai Nortye Ltd. American Depositary Shares's revenue grew +203.2% over the last year.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)